Clinical Trial Update: A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating JNJ-90301900 in combination with chemoradiation followed by consolidation immunotherapy for non-small cell lung cancer is cu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• JNJ-90301900

Snippet

Sponsor: Johnson & Johnson Enterprise Innovation Inc. | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: RECRUITING